Literature DB >> 16283619

Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities.

Miroslav Djokic1, Michelle M Le Beau, Lode J Swinnen, Sonali M Smith, Charles M Rubin, John Anastasi, Katrin M Carlson.   

Abstract

Although cytogenetic analysis advanced the understanding of the pathogenesis of primary non-Hodgkin lymphoma and led to improved clinical management, there have been no large cytogenetic studies of post-transplant lymphoproliferative disorder (PTLD). We examined the karyotypes of 36 PTLD cases and correlated them with clinical, laboratory, and pathologic findings. The cases included 2 early lesions, 13 polymorphic PTLDs, and 21 monomorphic PTLDs (18 B-cell and 3 T-cell proliferations). Cytogenetic abnormalities were identified in 72% of monomorphic B-cell PTLDs and in all T-cell PTLDs, but in only 15% of polymorphic PTLDs and in no early lesions. The most frequent clonal abnormalities in monomorphic PTLD were trisomies 9 and/or 11 (5 cases), followed by rearrangements of 8q24.1 (4 cases), 3q27 (2 cases), and 14q32 (2 cases). MYC rearrangement (8q24.1) and T-cell-associated chromosomal abnormalities correlated with poor outcome and short survival. PTLD with trisomy 9 and/or 11 developed early after transplant, presenting as Epstein-Barr virus-positive large B-cell lymphoma with prolonged survival.

Entities:  

Mesh:

Year:  2006        PMID: 16283619     DOI: 10.1002/gcc.20287

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  21 in total

1.  Physiological levels of reactive oxygen species are required to maintain genomic stability in stem cells.

Authors:  Tao-Sheng Li; Eduardo Marbán
Journal:  Stem Cells       Date:  2010-07       Impact factor: 6.277

Review 2.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

3.  ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

Authors:  Jennifer A Mertz; Ryuji Kobayashi; Jaquelin P Dudley
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey.

Authors:  Morteza Izadi; Mozhgan Fazel; Seyed Hasan Saadat; Saeed Taheri
Journal:  Hepatol Int       Date:  2011-03-30       Impact factor: 6.047

Review 5.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 6.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 7.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

Review 8.  Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

Authors:  Andrew M Evens; Rupali Roy; Danielle Sterrenberg; Michelle Z Moll; Amy Chadburn; Leo I Gordon
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 9.  Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.

Authors:  Zeina Al-Mansour; Beverly P Nelson; Andrew M Evens
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2.

Authors:  Daphne de Jong; Margaretha G M Roemer; John K C Chan; John Goodlad; Dita Gratzinger; Amy Chadburn; Elaine S Jaffe; Jonathan Said; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.